MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
5.40
-0.75
-12.20%
Opening 12:24 05/13 EDT
OPEN
5.75
PREV CLOSE
6.15
HIGH
5.96
LOW
5.16
VOLUME
109.25K
TURNOVER
--
52 WEEK HIGH
17.85
52 WEEK LOW
3.510
MARKET CAP
46.28M
P/E (TTM)
-0.5741
1D
5D
1M
3M
1Y
5Y
1D
Karyopharm Therapeutics Is Maintained at Overweight by Barclays
Dow Jones · 1h ago
Karyopharm Therapeutics Price Target Raised to $10.00/Share From $5.00 by Barclays
Dow Jones · 1h ago
Barclays Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $10
Benzinga · 1h ago
KARYOPHARM THERAPEUTICS INC <KPTI.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $8 FROM $26
Reuters · 3h ago
Karyopharm price target lowered to $33 from $43 at RBC Capital
TipRanks · 3h ago
Karyopharm Therapeutics Is Maintained at Outperform by Baird
Dow Jones · 3h ago
Karyopharm Therapeutics Price Target Cut to $42.00/Share From $54.00 by Baird
Dow Jones · 3h ago
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $42
Benzinga · 3h ago
More
About KPTI
More
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Recently
Symbol
Price
%Change

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.